Updates in Treatment of Refractory Inflammatory Myositis

Authors

  • Kun Huang, MD, PhD, FRCPC Department of Medicine, University of British Columbia, Vancouver, British Columbia Division of Rheumatology, Vancouver General Hospital, Vancouver, British Columbia Division of Rheumatology, Surrey Memorial Hospital, Surrey, British Columbia Arthritis Research Canada, Vancouver, British Columbia
  • Aidan Pye, MD Department of Medicine, University of British Columbia, Vancouver, British Columbia

Abstract

Idiopathic immune myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune diseases with varying phenotypes, prognoses, and treatment responses. They are primarily characterized by muscle inflammation, however, many patients have extramuscular involvement including skin rash, arthritis, interstitial lung disease (ILD), cardiomyopathy, and gastrointestinal dysmotility. The discovery of myositis-specific autoantibodies (MSAs) has been a major advancement in the field of IIMs, shaping the new landscape of the clinical, phenotypical, histological, and serological correlations. Based on this discovery, IIM can be more specifically classified into dermatomyositis (DM) (including amyopathic DM), antisynthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), polymyositis (PM), and overlap myositis (OM). An increasing number of histological studies have revealed a misdiagnosis of PM because many patients who were previously diagnosed with PM were later reclassified to other forms of IIM, including IBM, IMNM, ASyS, or DM without a rash.

Author Biographies

Kun Huang, MD, PhD, FRCPC, Department of Medicine, University of British Columbia, Vancouver, British Columbia Division of Rheumatology, Vancouver General Hospital, Vancouver, British Columbia Division of Rheumatology, Surrey Memorial Hospital, Surrey, British Columbia Arthritis Research Canada, Vancouver, British Columbia

Dr. Kun Huang is a rheumatologist at Surrey Memorial Hospital and a myositis specialist at the Mary Pack Arthritis Program at Vancouver Coastal Health. She is a clinical assistant professor at the University of British Columbia and a clinical investigator at the Arthritis Research Canada. She has an academic focus in inflammatory myositis therapies and outcome.

Aidan Pye, MD, Department of Medicine, University of British Columbia, Vancouver, British Columbia

Dr. Aidan Pye is a first-year internal medicine resident at the University of British Columbia with an interest in rheumatology. He completed his undergraduate degree in chemistry at the University of Victoria and MD at the University of British Columbia.

References

Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.

Loarce-Martos J, Lilleker JB, Parker M, McHugh N, Chinoy H. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Rheumatology (Oxford). 2021;60(7):3398-403.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314-24.

Aggarwal R, Charles-Schoeman C, Schessl J. Trial of Intravenous Immune Globulin in Dermatomyositis. Reply. N Engl J Med. 2023;388(1):94-5.

Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P, et al. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023;19(12):805-17.

Watanabe E, Gono T, Kuwana M, Terai C. Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis. Rheumatology (Oxford). 2020;59(3):586-93.

Pinard J, Femia AN, Roman M, Alsarheed A, Joyce C, Lin J, Vleugels RA. Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. JAMA Dermatol. 2019;155(4):494-6.

Cobos GA, Femia A, Vleugels RA. Dermatomyositis: An Update on Diagnosis and Treatment. Am J Clin Dermatol. 2020;21(3):339-53.

Wolstencroft PW, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. JAMA Dermatol. 2018;154(1):44-51.

Beckett M, Tan J, Bonnardeaux E, Dutz J, Shojania K, To F, et al. Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients. Rheumatology (Oxford). 2023.

Paik JJ, Lubin G, Gromatzky A, Mudd PN, Jr., Ponda MP, Christopher-Stine L. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2022.

Shneyderman M, Ahlawat S, Christopher-Stine L, Paik JJ. Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series. Rheumatology (Oxford). 2021;60(11):e387-e8.

Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases. J Autoimmun. 2019;100:131-6.

Werth VP, Aggarwal R, Charles-Schoeman C, Schessl J, Levine T, Kopasz N, et al. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study. EClinicalMedicine. 2023;64:102234.

Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol. 2012;148(4):455-62.

Jiang W, Yang H, Li S, Tian X, Wang G. Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study. Rheumatology (Oxford). 2021;60(6):2958-62.

Traineau H, Aggarwal R, Monfort JB, Senet P, Oddis CV, Chizzolini C, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. J Am Acad Dermatol. 2020;82(2):317-25.

Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017;56(2):247-54.

Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143(6):763-7.

Alexanderson H, Bostrom C. Exercise therapy in patients with idiopathic inflammatory myopathies and systemic lupus erythematosus - A systematic literature review. Best Pract Res Clin Rheumatol. 2020;34(2):101547.

Pijnenburg L, Giannini M, Bouchard-Marmen M, Arnaud L, Barsotti S, Bellando-Randone S, et al. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case-control study. RMD Open. 2023;9(3).

Kleefeld F, Uruha A, Schanzer A, Nishimura A, Roos A, Schneider U, et al. Morphologic and Molecular Patterns of Polymyositis With Mitochondrial Pathology and Inclusion Body Myositis. Neurology. 2022;99(20):e2212-e22.

Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci. 2009;278(1-2):25-9.

Naddaf E. Inclusion body myositis: Update on the diagnostic and therapeutic landscape. Front Neurol. 2022;13:1020113.

Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, et al. Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. Lung. 2016;194(5):733-7.

Hallowell RW, Danoff SK. Diagnosis and Management of Myositis-Associated Lung Disease. Chest. 2023;163(6):1476-91.

Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, Avina-Zubieta JA. Clinical spectrum andtherapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int. 2019;39(11):1971-81.

Johnson SR. American College of Rheumatology (ACR) Guideline for the Screening, Monitoring, and Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease 2023 Available from: https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltaedebda97a351d47/interstitial-lung-disease-guideline-summarytreatment-2023.pdf.

Aggarwal R, Lundberg IE, Song YW, Shaibani A, Werth VP, Maldonado MA. POS0839 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE EFFICACY AND SAFETY OF SCABATACEPT IN ADULTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY. Annals of the Rheumatic Diseases. 2022;81(Suppl 1):711-.

Oddis CV, Rockette HE, Zhu L, Koontz DC, Lacomis D, Venturupalli S, et al. Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis. ACR Open Rheumatol. 2022;4(11):983-90.

Beckett M, Dutz J, Huang K. Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients. RMD Open. 2024;10(1).

Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med. 2019;381(3):291-3.

Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56(9):3044-56.

Roccatello D, Fenoglio R, Caniggia I, Kamgaing J, Naretto C, Cecchi I, et al. Daratumumab monotherapy for refractory lupus nephritis. Nat Med. 2023;29(8):2041-7.

Landon-Cardinal O, Allard-Chamard H, Chapdelaine H, Doucet S, Rich E, Bourre-Tessier J. Daratumumab as a rescue therapy in severe refractory anti-SRP immunemediated necrotising myopathy. Ann Rheum Dis. 2023;82(4):579-80.

Holzer MT, Nies JF, Oqueka T, Huber TB, Kotter I, Krusche M. Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis. Chest. 2023;163(1):e1-e5.

Scheibe F, Ostendorf L, Pruss H, Radbruch H, Aschman T, Hoffmann S, et al. Daratumumab for treatmentrefractory antibody-mediated diseases in neurology. Eur J Neurol. 2022;29(6):1847-54.

Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416):2034-44.

Taubmann J, Knitza J, Muller F, Volkl S, Aigner M, Kleyer A, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies. Rheumatology (Oxford). 2023.

Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. JAMA. 2023;329(24):2154-62.

Muller F, Boeltz S, Knitza J, Aigner M, Volkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815-8.

Downloads

Published

2024-04-23

How to Cite

1.
Huang K, Pye A. Updates in Treatment of Refractory Inflammatory Myositis. Can Rheumatol Today [Internet]. 2024 Apr. 23 [cited 2024 Jun. 24];1(1):19–26. Available from: https://canadianrheumatologytoday.com/article/view/1-1-Huang_et_al

Issue

Section

Articles